论文部分内容阅读
4例慢性粒细胞白血病(CML)患者使用α-干扰素2a(IFN α-2a)治疗,起始剂量为3×10~6IU/d,皮下注射。然后剂量增至9×10~6IU/d,并保持在最大耐受剂量。用巢式PCR法监测BCR/ABL嵌合基因,结果IFN α-2a治疗后,例1在10个月、例2和例3在12个月及例4在23个月时Ph阳性克隆完全抑制,遂用PCR检测BCR/ABL嵌合基因。例1第9个月至第30个月连续6次PCR检查外周血和骨髓细胞BCR/ABL嵌合基因阴性,但IFN2a剂量从
Four patients with chronic myeloid leukemia (CML) were treated with IFN-α 2a (3 × 10 ~ 6 IU / d, subcutaneously). Then the dose increased to 9 × 10 ~ 6IU / d, and maintained at the maximum tolerated dose. BCR / ABL chimeric genes were monitored by nested PCR. As a result, Ph positive clones were completely inhibited at 10 months, in cases 2 and 3 at 12 months and cases 4 and 23 months after IFNα-2a treatment , Then PCR detection of BCR / ABL chimeric genes. Example 1 BCR / ABL chimeric genes were negative in peripheral blood and bone marrow cells from 6th to 6th consecutive PCR from the 9th month to the 30th month in Example 1, but the dose of IFN2a was